APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

GLP-1 Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global GLP-1 Drug Market Outlook and Growth Opportunities 2026

Report ID 173995400429 December 2025195 pages

Choose your research edition.

Industry ResearchGLP-1 Drug Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal GLP-1 Drug Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal GLP-1 Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GLP-1 Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal GLP-1 Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global GLP-1 Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for GLP-1 Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GLP-1 Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GLP-1 Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the GLP-1 Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the GLP-1 Drug market include AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline (GSK), Hanmi Pharmaceutical Co, Novo Nordisk, Pfizer Inc, Sanofi and Teva Pharmaceutical Industries Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global GLP-1 Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GLP-1 Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GLP-1 Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the GLP-1 Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

GLP-1 Drug Segment by Company

AstraZeneca

Boehringer Ingelheim

Eli Lilly

GlaxoSmithKline (GSK)

Hanmi Pharmaceutical Co

Novo Nordisk

Pfizer Inc

Sanofi

Teva Pharmaceutical Industries Ltd

Gan & Lee Pharmaceuticals

Huadong Medicine

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

PegBio Co., Ltd

Shanghai Benemae Pharmaceutical Corporation

Tonghua Dongbao

GLP-1 Drug Segment by Type

Short-acting GLP-1 Drug

Long-acting GLP-1 Drug

GLP-1 Drug Segment by Application

Type 2 Diabetes (T2DM)

Alzheimer's Disease (AD)

Non-alcoholic Steatohepatitis (NASH)

Obesity

Cardiovascular and Cerebrovascular Diseases (CVD)

GLP-1 Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global GLP-1 Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions GLP-1 Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify GLP-1 Drug significant trends, drivers, influence factors in global and regions.

6. To analyze GLP-1 Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the GLP-1 Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GLP-1 Drug industry.

Chapter 3: Detailed analysis of GLP-1 Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of GLP-1 Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of GLP-1 Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. GLP-1 Drug Industry Trends Table 2. GLP-1 Drug Industry Drivers Table 3. GLP-1 Drug Industry Opportunities and Challenges Table 4. GLP-1 Drug Industry Restraints Table 5. Global GLP-1 Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global GLP-1 Drug Revenue Share by Company (2021-2026) Table 7. Global GLP-1 Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global GLP-1 Drug Sales Volume Share by Company (2021-2026) Table 9. Global GLP-1 Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global GLP-1 Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global GLP-1 Drug Key Company Manufacturing Base & Headquarters Table 12. Global GLP-1 Drug Company, Product Type & Application Table 13. Global GLP-1 Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global GLP-1 Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Short-acting GLP-1 Drug Table 18. Significant Companies of Long-acting GLP-1 Drug Table 19. Global GLP-1 Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global GLP-1 Drug Sales Volume by Type (2021-2026) & (K Units) Table 21. Global GLP-1 Drug Sales Volume by Type (2027-2032) & (K Units) Table 22. Global GLP-1 Drug Sales Volume Share by Type (2021-2026) Table 23. Global GLP-1 Drug Sales Volume Share by Type (2027-2032) Table 24. Global GLP-1 Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global GLP-1 Drug Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global GLP-1 Drug Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global GLP-1 Drug Sales Value Share by Type (2021-2026) Table 28. Global GLP-1 Drug Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Type 2 Diabetes (T2DM) Table 30. Significant Companies of Alzheimer's Disease (AD) Table 31. Significant Companies of Non-alcoholic Steatohepatitis (NASH) Table 32. Significant Companies of Obesity Table 33. Significant Companies of Cardiovascular and Cerebrovascular Diseases (CVD) Table 34. Global GLP-1 Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global GLP-1 Drug Sales Volume by Application (2021-2026) & (K Units) Table 36. Global GLP-1 Drug Sales Volume by Application (2027-2032) & (K Units) Table 37. Global GLP-1 Drug Sales Volume Share by Application (2021-2026) Table 38. Global GLP-1 Drug Sales Volume Share by Application (2027-2032) Table 39. Global GLP-1 Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global GLP-1 Drug Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global GLP-1 Drug Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global GLP-1 Drug Sales Value Share by Application (2021-2026) Table 43. Global GLP-1 Drug Sales Value Share by Application (2027-2032) Table 44. Global GLP-1 Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global GLP-1 Drug Sales by Region (2021-2026) & (K Units) Table 46. Global GLP-1 Drug Sales Market Share by Region (2021-2026) Table 47. Global GLP-1 Drug Sales by Region (2027-2032) & (K Units) Table 48. Global GLP-1 Drug Sales Market Share by Region (2027-2032) Table 49. Global GLP-1 Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global GLP-1 Drug Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global GLP-1 Drug Sales Value Share by Region (2021-2026) Table 52. Global GLP-1 Drug Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global GLP-1 Drug Sales Value Share by Region (2027-2032) Table 54. Global GLP-1 Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global GLP-1 Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global GLP-1 Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global GLP-1 Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global GLP-1 Drug Sales by Country (2021-2026) & (K Units) Table 59. Global GLP-1 Drug Sales Market Share by Country (2021-2026) Table 60. Global GLP-1 Drug Sales by Country (2027-2032) & (K Units) Table 61. Global GLP-1 Drug Sales Market Share by Country (2027-2032) Table 62. Global GLP-1 Drug Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global GLP-1 Drug Sales Value Market Share by Country (2021-2026) Table 64. Global GLP-1 Drug Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global GLP-1 Drug Sales Value Market Share by Country (2027-2032) Table 66. AstraZeneca Company Information Table 67. AstraZeneca Business Overview Table 68. AstraZeneca GLP-1 Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. AstraZeneca GLP-1 Drug Product Portfolio Table 70. AstraZeneca Recent Development Table 71. Boehringer Ingelheim Company Information Table 72. Boehringer Ingelheim Business Overview Table 73. Boehringer Ingelheim GLP-1 Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Boehringer Ingelheim GLP-1 Drug Product Portfolio Table 75. Boehringer Ingelheim Recent Development Table 76. Eli Lilly Company Information Table 77. Eli Lilly Business Overview Table 78. Eli Lilly GLP-1 Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Eli Lilly GLP-1 Drug Product Portfolio Table 80. Eli Lilly Recent Development Table 81. GlaxoSmithKline (GSK) Company Information Table 82. GlaxoSmithKline (GSK) Business Overview Table 83. GlaxoSmithKline (GSK) GLP-1 Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. GlaxoSmithKline (GSK) GLP-1 Drug Product Portfolio Table 85. GlaxoSmithKline (GSK) Recent Development Table 86. Hanmi Pharmaceutical Co Company Information Table 87. Hanmi Pharmaceutical Co Business Overview Table 88. Hanmi Pharmaceutical Co GLP-1 Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Hanmi Pharmaceutical Co GLP-1 Drug Product Portfolio Table 90. Hanmi Pharmaceutical Co Recent Development Table 91. Novo Nordisk Company Information Table 92. Novo Nordisk Business Overview Table 93. Novo Nordisk GLP-1 Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Novo Nordisk GLP-1 Drug Product Portfolio Table 95. Novo Nordisk Recent Development Table 96. Pfizer Inc Company Information Table 97. Pfizer Inc Business Overview Table 98. Pfizer Inc GLP-1 Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Pfizer Inc GLP-1 Drug Product Portfolio Table 100. Pfizer Inc Recent Development Table 101. Sanofi Company Information Table 102. Sanofi Business Overview Table 103. Sanofi GLP-1 Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Sanofi GLP-1 Drug Product Portfolio Table 105. Sanofi Recent Development Table 106. Teva Pharmaceutical Industries Ltd Company Information Table 107. Teva Pharmaceutical Industries Ltd Business Overview Table 108. Teva Pharmaceutical Industries Ltd GLP-1 Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Teva Pharmaceutical Industries Ltd GLP-1 Drug Product Portfolio Table 110. Teva Pharmaceutical Industries Ltd Recent Development Table 111. Gan & Lee Pharmaceuticals Company Information Table 112. Gan & Lee Pharmaceuticals Business Overview Table 113. Gan & Lee Pharmaceuticals GLP-1 Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Gan & Lee Pharmaceuticals GLP-1 Drug Product Portfolio Table 115. Gan & Lee Pharmaceuticals Recent Development Table 116. Huadong Medicine Company Information Table 117. Huadong Medicine Business Overview Table 118. Huadong Medicine GLP-1 Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Huadong Medicine GLP-1 Drug Product Portfolio Table 120. Huadong Medicine Recent Development Table 121. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Company Information Table 122. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Business Overview Table 123. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. GLP-1 Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. GLP-1 Drug Product Portfolio Table 125. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Recent Development Table 126. PegBio Co., Ltd Company Information Table 127. PegBio Co., Ltd Business Overview Table 128. PegBio Co., Ltd GLP-1 Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. PegBio Co., Ltd GLP-1 Drug Product Portfolio Table 130. PegBio Co., Ltd Recent Development Table 131. Shanghai Benemae Pharmaceutical Corporation Company Information Table 132. Shanghai Benemae Pharmaceutical Corporation Business Overview Table 133. Shanghai Benemae Pharmaceutical Corporation GLP-1 Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Shanghai Benemae Pharmaceutical Corporation GLP-1 Drug Product Portfolio Table 135. Shanghai Benemae Pharmaceutical Corporation Recent Development Table 136. Tonghua Dongbao Company Information Table 137. Tonghua Dongbao Business Overview Table 138. Tonghua Dongbao GLP-1 Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Tonghua Dongbao GLP-1 Drug Product Portfolio Table 140. Tonghua Dongbao Recent Development Table 141. Key Raw Materials Table 142. Raw Materials Key Suppliers Table 143. GLP-1 Drug Distributors List Table 144. GLP-1 Drug Customers List Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. GLP-1 Drug Product Image Figure 2. Global GLP-1 Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GLP-1 Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global GLP-1 Drug Sales (2021-2032) & (K Units) Figure 5. Global GLP-1 Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global GLP-1 Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Short-acting GLP-1 Drug Image Figure 10. Long-acting GLP-1 Drug Image Figure 11. Global GLP-1 Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global GLP-1 Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global GLP-1 Drug Sales Volume Share by Type (2021-2032) Figure 14. Global GLP-1 Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global GLP-1 Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global GLP-1 Drug Sales Value Share by Type (2021-2032) Figure 17. Type 2 Diabetes (T2DM) Image Figure 18. Alzheimer's Disease (AD) Image Figure 19. Non-alcoholic Steatohepatitis (NASH) Image Figure 20. Obesity Image Figure 21. Cardiovascular and Cerebrovascular Diseases (CVD) Image Figure 22. Global GLP-1 Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global GLP-1 Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global GLP-1 Drug Sales Volume Share by Application (2021-2032) Figure 25. Global GLP-1 Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global GLP-1 Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global GLP-1 Drug Sales Value Share by Application (2021-2032) Figure 28. Global GLP-1 Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global GLP-1 Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global GLP-1 Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global GLP-1 Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America GLP-1 Drug Sales Value (2021-2032) & (US$ Million) Figure 33. North America GLP-1 Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe GLP-1 Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Europe GLP-1 Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific GLP-1 Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific GLP-1 Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America GLP-1 Drug Sales Value (2021-2032) & (US$ Million) Figure 39. South America GLP-1 Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa GLP-1 Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa GLP-1 Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt GLP-1 Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt GLP-1 Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt GLP-1 Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. GLP-1 Drug Value Chain Figure 127. Manufacturing Cost Structure Figure 128. GLP-1 Drug Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Short-acting GLP-1 Drug
  • Long-acting GLP-1 Drug
Applications
  • Type 2 Diabetes (T2DM)
  • Alzheimer's Disease (AD)
  • Non-alcoholic Steatohepatitis (NASH)
  • Obesity
  • Cardiovascular and Cerebrovascular Diseases (CVD)
Companies covered
  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lilly
  • GlaxoSmithKline (GSK)
  • Hanmi Pharmaceutical Co
  • Novo Nordisk
  • Pfizer Inc
  • Sanofi
  • Teva Pharmaceutical Industries Ltd
  • Gan & Lee Pharmaceuticals
  • Huadong Medicine
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • PegBio Co., Ltd
  • Shanghai Benemae Pharmaceutical Corporation
  • Tonghua Dongbao

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global GLP-1 Drug Sales Value (2021-2032)
  4. 1.2.2 Global GLP-1 Drug Sales Volume (2021-2032)
  5. 1.2.3 Global GLP-1 Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 GLP-1 Drug Market Dynamics
  1. 2.1 GLP-1 Drug Industry Trends
  2. 2.2 GLP-1 Drug Industry Drivers
  3. 2.3 GLP-1 Drug Industry Opportunities and Challenges
  4. 2.4 GLP-1 Drug Industry Restraints
3 GLP-1 Drug Market by Company
  1. 3.1 Global GLP-1 Drug Company Revenue Ranking in 2025
  2. 3.2 Global GLP-1 Drug Revenue by Company (2021-2026)
  3. 3.3 Global GLP-1 Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global GLP-1 Drug Average Price by Company (2021-2026)
  5. 3.5 Global GLP-1 Drug Company Ranking (2024-2026)
  6. 3.6 Global GLP-1 Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global GLP-1 Drug Company Product Type and Application
  8. 3.8 Global GLP-1 Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global GLP-1 Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 GLP-1 Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 GLP-1 Drug Market by Type
  1. 4.1 GLP-1 Drug Type Introduction
  2. 4.1.1 Short-acting GLP-1 Drug
  3. 4.1.2 Long-acting GLP-1 Drug
  4. 4.2 Global GLP-1 Drug Sales Volume by Type
  5. 4.2.1 Global GLP-1 Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global GLP-1 Drug Sales Volume by Type (2021-2032)
  7. 4.2.3 Global GLP-1 Drug Sales Volume Share by Type (2021-2032)
  8. 4.3 Global GLP-1 Drug Sales Value by Type
  9. 4.3.1 Global GLP-1 Drug Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global GLP-1 Drug Sales Value by Type (2021-2032)
  11. 4.3.3 Global GLP-1 Drug Sales Value Share by Type (2021-2032)
5 GLP-1 Drug Market by Application
  1. 5.1 GLP-1 Drug Application Introduction
  2. 5.1.1 Type 2 Diabetes (T2DM)
  3. 5.1.2 Alzheimer's Disease (AD)
  4. 5.1.3 Non-alcoholic Steatohepatitis (NASH)
  5. 5.1.4 Obesity
  6. 5.1.5 Cardiovascular and Cerebrovascular Diseases (CVD)
  7. 5.2 Global GLP-1 Drug Sales Volume by Application
  8. 5.2.1 Global GLP-1 Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global GLP-1 Drug Sales Volume by Application (2021-2032)
  10. 5.2.3 Global GLP-1 Drug Sales Volume Share by Application (2021-2032)
  11. 5.3 Global GLP-1 Drug Sales Value by Application
  12. 5.3.1 Global GLP-1 Drug Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global GLP-1 Drug Sales Value by Application (2021-2032)
  14. 5.3.3 Global GLP-1 Drug Sales Value Share by Application (2021-2032)
6 GLP-1 Drug Regional Sales and Value Analysis
  1. 6.1 Global GLP-1 Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GLP-1 Drug Sales by Region (2021-2032)
  3. 6.2.1 Global GLP-1 Drug Sales by Region: 2021-2026
  4. 6.2.2 Global GLP-1 Drug Sales by Region (2027-2032)
  5. 6.3 Global GLP-1 Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global GLP-1 Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global GLP-1 Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global GLP-1 Drug Sales Value by Region (2027-2032)
  9. 6.5 Global GLP-1 Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America GLP-1 Drug Sales Value (2021-2032)
  12. 6.6.2 North America GLP-1 Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe GLP-1 Drug Sales Value (2021-2032)
  15. 6.7.2 Europe GLP-1 Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific GLP-1 Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific GLP-1 Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America GLP-1 Drug Sales Value (2021-2032)
  21. 6.9.2 South America GLP-1 Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa GLP-1 Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa GLP-1 Drug Sales Value Share by Country, 2025 VS 2032
7 GLP-1 Drug Country-level Sales and Value Analysis
  1. 7.1 Global GLP-1 Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global GLP-1 Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global GLP-1 Drug Sales by Country (2021-2032)
  4. 7.3.1 Global GLP-1 Drug Sales by Country (2021-2026)
  5. 7.3.2 Global GLP-1 Drug Sales by Country (2027-2032)
  6. 7.4 Global GLP-1 Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global GLP-1 Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global GLP-1 Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA GLP-1 Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada GLP-1 Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico GLP-1 Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany GLP-1 Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France GLP-1 Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. GLP-1 Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy GLP-1 Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain GLP-1 Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia GLP-1 Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands GLP-1 Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries GLP-1 Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China GLP-1 Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan GLP-1 Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea GLP-1 Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India GLP-1 Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia GLP-1 Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia GLP-1 Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil GLP-1 Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina GLP-1 Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile GLP-1 Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia GLP-1 Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru GLP-1 Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia GLP-1 Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel GLP-1 Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE GLP-1 Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey GLP-1 Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran GLP-1 Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt GLP-1 Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt GLP-1 Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt GLP-1 Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca
  2. 8.1.1 AstraZeneca Company Information
  3. 8.1.2 AstraZeneca Business Overview
  4. 8.1.3 AstraZeneca GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca GLP-1 Drug Product Portfolio
  6. 8.1.5 AstraZeneca Recent Developments
  7. 8.2 Boehringer Ingelheim
  8. 8.2.1 Boehringer Ingelheim Company Information
  9. 8.2.2 Boehringer Ingelheim Business Overview
  10. 8.2.3 Boehringer Ingelheim GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Boehringer Ingelheim GLP-1 Drug Product Portfolio
  12. 8.2.5 Boehringer Ingelheim Recent Developments
  13. 8.3 Eli Lilly
  14. 8.3.1 Eli Lilly Company Information
  15. 8.3.2 Eli Lilly Business Overview
  16. 8.3.3 Eli Lilly GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly GLP-1 Drug Product Portfolio
  18. 8.3.5 Eli Lilly Recent Developments
  19. 8.4 GlaxoSmithKline (GSK)
  20. 8.4.1 GlaxoSmithKline (GSK) Company Information
  21. 8.4.2 GlaxoSmithKline (GSK) Business Overview
  22. 8.4.3 GlaxoSmithKline (GSK) GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline (GSK) GLP-1 Drug Product Portfolio
  24. 8.4.5 GlaxoSmithKline (GSK) Recent Developments
  25. 8.5 Hanmi Pharmaceutical Co
  26. 8.5.1 Hanmi Pharmaceutical Co Company Information
  27. 8.5.2 Hanmi Pharmaceutical Co Business Overview
  28. 8.5.3 Hanmi Pharmaceutical Co GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Hanmi Pharmaceutical Co GLP-1 Drug Product Portfolio
  30. 8.5.5 Hanmi Pharmaceutical Co Recent Developments
  31. 8.6 Novo Nordisk
  32. 8.6.1 Novo Nordisk Company Information
  33. 8.6.2 Novo Nordisk Business Overview
  34. 8.6.3 Novo Nordisk GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Novo Nordisk GLP-1 Drug Product Portfolio
  36. 8.6.5 Novo Nordisk Recent Developments
  37. 8.7 Pfizer Inc
  38. 8.7.1 Pfizer Inc Company Information
  39. 8.7.2 Pfizer Inc Business Overview
  40. 8.7.3 Pfizer Inc GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Inc GLP-1 Drug Product Portfolio
  42. 8.7.5 Pfizer Inc Recent Developments
  43. 8.8 Sanofi
  44. 8.8.1 Sanofi Company Information
  45. 8.8.2 Sanofi Business Overview
  46. 8.8.3 Sanofi GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi GLP-1 Drug Product Portfolio
  48. 8.8.5 Sanofi Recent Developments
  49. 8.9 Teva Pharmaceutical Industries Ltd
  50. 8.9.1 Teva Pharmaceutical Industries Ltd Company Information
  51. 8.9.2 Teva Pharmaceutical Industries Ltd Business Overview
  52. 8.9.3 Teva Pharmaceutical Industries Ltd GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Teva Pharmaceutical Industries Ltd GLP-1 Drug Product Portfolio
  54. 8.9.5 Teva Pharmaceutical Industries Ltd Recent Developments
  55. 8.10 Gan & Lee Pharmaceuticals
  56. 8.10.1 Gan & Lee Pharmaceuticals Company Information
  57. 8.10.2 Gan & Lee Pharmaceuticals Business Overview
  58. 8.10.3 Gan & Lee Pharmaceuticals GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Gan & Lee Pharmaceuticals GLP-1 Drug Product Portfolio
  60. 8.10.5 Gan & Lee Pharmaceuticals Recent Developments
  61. 8.11 Huadong Medicine
  62. 8.11.1 Huadong Medicine Company Information
  63. 8.11.2 Huadong Medicine Business Overview
  64. 8.11.3 Huadong Medicine GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Huadong Medicine GLP-1 Drug Product Portfolio
  66. 8.11.5 Huadong Medicine Recent Developments
  67. 8.12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  68. 8.12.1 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Company Information
  69. 8.12.2 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Business Overview
  70. 8.12.3 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. GLP-1 Drug Product Portfolio
  72. 8.12.5 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Recent Developments
  73. 8.13 PegBio Co., Ltd
  74. 8.13.1 PegBio Co., Ltd Company Information
  75. 8.13.2 PegBio Co., Ltd Business Overview
  76. 8.13.3 PegBio Co., Ltd GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 PegBio Co., Ltd GLP-1 Drug Product Portfolio
  78. 8.13.5 PegBio Co., Ltd Recent Developments
  79. 8.14 Shanghai Benemae Pharmaceutical Corporation
  80. 8.14.1 Shanghai Benemae Pharmaceutical Corporation Company Information
  81. 8.14.2 Shanghai Benemae Pharmaceutical Corporation Business Overview
  82. 8.14.3 Shanghai Benemae Pharmaceutical Corporation GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Shanghai Benemae Pharmaceutical Corporation GLP-1 Drug Product Portfolio
  84. 8.14.5 Shanghai Benemae Pharmaceutical Corporation Recent Developments
  85. 8.15 Tonghua Dongbao
  86. 8.15.1 Tonghua Dongbao Company Information
  87. 8.15.2 Tonghua Dongbao Business Overview
  88. 8.15.3 Tonghua Dongbao GLP-1 Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Tonghua Dongbao GLP-1 Drug Product Portfolio
  90. 8.15.5 Tonghua Dongbao Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 GLP-1 Drug Value Chain Analysis
  2. 9.1.1 GLP-1 Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 GLP-1 Drug Sales Mode & Process
  6. 9.2 GLP-1 Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 GLP-1 Drug Distributors
  9. 9.2.3 GLP-1 Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst